Autopsy report · NCT03470350

Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer

“No study drug available. Same concept with new study drug will be explored in M19TGA study”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

The Netherlands Cancer Institute

Sponsor type

University, hospital or other

Conditions

Colorectal Cancer Metastatic

Interventions

Galunisertib

Participants

0

Sites

1

Countries

Netherlands

Trials that died the same way

• A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
  “One of the drugs for the study is not commercially available.” (75% match in meaning)
• CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
  “Study drug no longer available” (73% match in meaning)
• Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
  “study drug unavailable” (73% match in meaning)
• P1101 in Treating Patients With Myelofibrosis
  “Study drug became commercially available” (73% match in meaning)
• Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
  “Study drug is now commercially available in tablet format” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.